Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study-Reference-Cited by-同舟云学术

Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study

Published:2023-11-30 Issue: Volume: Page:
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Biesdorf Carla^ORCID,Guan Xiaowen^ORCID,Siddani Satya R.,Hoffman David,Boehm Nils,Medeiros Bruno C.,Doi Toshihiko,de Jonge Maja,Rasco Drew,Menon Rajeev M.^ORCID,Polepally Akshanth R.^ORCID

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-023-04613-9.pdf

Reference28 articles.

1. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782–798. https://doi.org/10.1038/nrc2465

2. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420–430. https://doi.org/10.1038/nrc821

3. Lemke J, von Karstedt S, Zinngrebe J, Walczak H (2014) Getting TRAIL back on track for cancer therapy. Cell Death Differ 21:1350–1364. https://doi.org/10.1038/cdd.2014.81

4. Holland PM (2014) Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev 25:185–193. https://doi.org/10.1016/j.cytogfr.2013.12.009

5. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31–38